Cambridge Medical Robotics Secures $20.3M Series A Funding to Advance Next-Gen Surgical Robotics Platform

On July 18, Cambridge Medical Robotics (CMR), a privately held company specializing in robotic system development, announced the completion of a $20.3 million Series A financing round, with participation from ABB Technology Ventures, LGT Global Invest, and Cambridge Innovation Capital. The company plans to leverage this funding to advance the development and commercialization of its medical robotics technologies, expand its workforce, and better prepare for regulatory approvals.

Cambridge Medical Robotics, founded in 2014 and headquartered in Cambridge, UK, is dedicated to developing next-generation general-purpose robotic systems for minimally invasive surgery. The company aims to broaden the scope of procedures performed by its robotic systems, thereby making minimally invasive surgery accessible to a larger patient population at an affordable cost. This system is poised to transform the current landscape of the robotic surgery market. Currently, the global annual revenue from robot-assisted minimally invasive surgeries stands at approximately $4 billion, with projections indicating it will reach $20 billion by 2025. Following the successful initiation of clinical specimen trials in June this year, CMR’s latest round of financing will further accelerate its transition into a global medical device supplier.

Commenting on the successful completion of this financing round, Martin Frost, CEO of CMR, stated, “We are delighted that these leading international investors have recognized and supported us. This financing will enable us to increase our investment in target markets and prepare for commercialization. We look forward to collaborating with ABB throughout the entire process, from component procurement to manufacturing, as our company’s production and commercialization efforts have now entered a critical phase.”

Reynir Indahl, Chairman of CMR, added, “This funding round marks a revolutionary milestone, as CMR has achieved positive results in clinical specimen testing and is now striving to become the first to launch a fully universal and affordable robotic system on the market, thereby expanding the range of procedures currently performed by robots.”

Girish Nadkarni, President of ABB Technology Ventures, commented, “ABB invested in CMR because we see CMR as capable of providing a next-generation platform for minimally invasive surgery. Currently, demand in the healthcare industry is continuously expanding, so this field holds immense development potential. Furthermore, as the robotics world moves toward fully general-purpose, collaborative robotic systems, CMR’s robotic technology will have broader application prospects.”

Dr. Robert Tansley from CIC stated, “Cambridge is a globally recognized cluster of world-class enterprises in both the life sciences and technology sectors. CMR is a typical innovative company within this ecosystem and represents the type of investment target we are seeking. The company is poised to bring revolutionary changes to the field of surgical robotics by leveraging interdisciplinary network technologies.”